(Bloomberg) -- Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat ...

Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's ...

On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle. Regeneron is the facility’s third ...

Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed a $3 billion agreement to make treatments for Regeneron Pharmaceuticals.

FUJIFILM Diosynth Biotechnologies signed a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals to provide U.S.-based production of its biologic medicines.

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug—that ...

Fujifilm Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced a 10-year manufacturing supply ...

Regeneron Pharmaceuticals, which garnered attention in 2020 when President Donald Trump touted the company's experimental COVID-19 vaccine as a "cure," said Monday, May 19, that it will buy ...

Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth. Boehringer Ingelheim and Tessellate Bio entered into a research collaboration and ...

Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies.